<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519867</url>
  </required_header>
  <id_info>
    <org_study_id>P06387</org_study_id>
    <secondary_id>MK-8616-042</secondary_id>
    <secondary_id>19.4.204</secondary_id>
    <nct_id>NCT03519867</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042)</brief_title>
  <official_title>A Multi-center, Randomized, Assessor-blinded, Phase II, Parallel Dose-finding Trial in Subjects of ASA Class 1 - 3 to Assess the Efficacy and Safety of 5 Doses of Org 25969 When Administered at 1-2 PTCs After Administration of Zemuron®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to explore the dose-response relation of MK-8616 (Org
      25969) given as a reversal agent of Zemuron® at 1 to 2 post tetanic counts (PTCs); both
      Zemuron® and MK-8616 are administered by intravenous (iv) infusion. Another goal of the study
      is to evaluate the safety of single doses of MK-8616 administered in participants of American
      Society of Anesthesiologists (ASA) Physical Status Class 1 (otherwise normal, healthy
      participant); Class 2 (participant with a mild systemic disease); or Class 3 (participant
      with a severe systemic disease that limits activity, but is not incapacitating).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2004</start_date>
  <completion_date type="Actual">May 26, 2005</completion_date>
  <primary_completion_date type="Actual">May 26, 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from start of administration of MK-8616 to recovery T4/T1 ratio to 0.9</measure>
    <time_frame>Up to 30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing an adverse event (AE)</measure>
    <time_frame>Up to 7 days following MK-8616 administration</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>1) Zemuron® 0.6 mg/kg + MK-8616 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2) Zemuron® 1.2 mg/kg + MK-8616 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3) Zemuron® 0.6 mg/kg + MK-8616 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4) Zemuron® 1.2 mg/kg + MK-8616 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5) Zemuron® 0.6 mg/kg + MK-8616 2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6) Zemuron® 1.2 mg/kg + MK-8616 2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7) Zemuron® 0.6 mg/kg + MK-8616 4.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8) Zemuron® 1.2 mg/kg + MK-8616 4.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9) Zemuron® 0.6 mg/kg + MK-8616 8.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10) Zemuron® 1.2 mg/kg + MK-8616 8.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8616</intervention_name>
    <description>MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion. Doses are based on actual body weight.</description>
    <arm_group_label>1) Zemuron® 0.6 mg/kg + MK-8616 0.5 mg/kg</arm_group_label>
    <arm_group_label>2) Zemuron® 1.2 mg/kg + MK-8616 0.5 mg/kg</arm_group_label>
    <arm_group_label>3) Zemuron® 0.6 mg/kg + MK-8616 1.0 mg/kg</arm_group_label>
    <arm_group_label>4) Zemuron® 1.2 mg/kg + MK-8616 1.0 mg/kg</arm_group_label>
    <arm_group_label>5) Zemuron® 0.6 mg/kg + MK-8616 2.0 mg/kg</arm_group_label>
    <arm_group_label>6) Zemuron® 1.2 mg/kg + MK-8616 2.0 mg/kg</arm_group_label>
    <arm_group_label>7) Zemuron® 0.6 mg/kg + MK-8616 4.0 mg/kg</arm_group_label>
    <arm_group_label>8) Zemuron® 1.2 mg/kg + MK-8616 4.0 mg/kg</arm_group_label>
    <arm_group_label>9) Zemuron® 0.6 mg/kg + MK-8616 8.0 mg/kg</arm_group_label>
    <arm_group_label>10) Zemuron® 1.2 mg/kg + MK-8616 8.0 mg/kg</arm_group_label>
    <other_name>Org 25969, sugammadex, Bridion®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zemuron®</intervention_name>
    <description>Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs. If needed, a maintenance dose of 0.15 mg/kg will be given. Doses are based on actual body weight.</description>
    <arm_group_label>1) Zemuron® 0.6 mg/kg + MK-8616 0.5 mg/kg</arm_group_label>
    <arm_group_label>2) Zemuron® 1.2 mg/kg + MK-8616 0.5 mg/kg</arm_group_label>
    <arm_group_label>3) Zemuron® 0.6 mg/kg + MK-8616 1.0 mg/kg</arm_group_label>
    <arm_group_label>4) Zemuron® 1.2 mg/kg + MK-8616 1.0 mg/kg</arm_group_label>
    <arm_group_label>5) Zemuron® 0.6 mg/kg + MK-8616 2.0 mg/kg</arm_group_label>
    <arm_group_label>6) Zemuron® 1.2 mg/kg + MK-8616 2.0 mg/kg</arm_group_label>
    <arm_group_label>7) Zemuron® 0.6 mg/kg + MK-8616 4.0 mg/kg</arm_group_label>
    <arm_group_label>8) Zemuron® 1.2 mg/kg + MK-8616 4.0 mg/kg</arm_group_label>
    <arm_group_label>9) Zemuron® 0.6 mg/kg + MK-8616 8.0 mg/kg</arm_group_label>
    <arm_group_label>10) Zemuron® 1.2 mg/kg + MK-8616 8.0 mg/kg</arm_group_label>
    <other_name>Rocuronium bromide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has an ASA Class of 1 to 3

          -  Is scheduled for surgical procedures (excluding dental and neck surgeries) with an
             anticipated duration of anesthesia of ≥45 minutes with the use of Zemeron®

        Exclusion Criteria:

          -  Is undergoing dental or neck surgery

          -  Has anatomical malformation that would impede intubation

          -  Has or is suspected to have neuromuscular disorders impairing neuromuscular block
             and/or significant renal dysfunction

          -  Is known or suspected to have a family history of malignant hyperthermia

          -  Is known or suspected to have an allergy to narcotics, muscle relaxants, or other
             medications used during general anesthesia

          -  Is pregnant

          -  Is a female of childbearing potential not using 1 of the following methods of birth
             control: condom or diaphragm with spermicide, vasectomized partner (&lt;6 months),
             intrauterine device (IUD), or abstinence

          -  Is breast-feeding

          -  Has already participated in the study

          -  Has participated in another clinical trial, not pre-approved by Organon
             Pharmaceuticals USA within 30 days of entering this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

